These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 18826102)

  • 1. [Proteasome inhibitor bortezomib sensitizes Hep-2 human laryngeal squamous cell carcinoma cells to ionizing radiation in vitro and in vivo].
    Wang QW; Liu H; Liang YM; Wang T; Zhu XD
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Jun; 43(6):456-9. PubMed ID: 18826102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).
    Kamer S; Ren Q; Dicker AP
    Arch Gynecol Obstet; 2009 Jan; 279(1):41-6. PubMed ID: 18461345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiosensitizing properties of bortezomib depend on therapeutic schedule.
    Labussière M; Pinel S; Vandamme M; Plénat F; Chastagner P
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):892-900. PubMed ID: 21168283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT3 blockade with shRNA enhances radiosensitivity in Hep-2 human laryngeal squamous carcinoma cells.
    Li X; Wang H; Lu X; Di B
    Oncol Rep; 2010 Feb; 23(2):345-53. PubMed ID: 20043094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibitor bortezomi-induced the apoptosis of laryngeal squamous cell carcinoma Hep-2 cell line via disrupting redox equilibrium.
    Yang X
    Biomed Pharmacother; 2012 Dec; 66(8):607-11. PubMed ID: 23089480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The proteasome inhibitor PS-341 in cancer therapy.
    Teicher BA; Ara G; Herbst R; Palombella VJ; Adams J
    Clin Cancer Res; 1999 Sep; 5(9):2638-45. PubMed ID: 10499643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [hTERT promoter enhances the radiosensitivity to gene-radiation therapy of human laryngeal carcinoma transplanted in nude mice].
    Huang CH; Liao ZK; Zhou FX; Wang WF; Xie CH; Zhang HY; Sun WJ; Zhou YF
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):733-6. PubMed ID: 19173799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
    Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
    Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
    O'Connor OA; Smith EA; Toner LE; Teruya-Feldstein J; Frankel S; Rolfe M; Wei X; Liu S; Marcucci G; Chan KK; Chanan-Khan A
    Clin Cancer Res; 2006 May; 12(9):2902-11. PubMed ID: 16675587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of human respiratory syncytial virus infected Balb/C mice with the proteasome inhibitor bortezomib (Velcade, PS-341) results in increased inflammation and mortality.
    Lupfer C; Patton KM; Pastey MK
    Toxicology; 2010 Jan; 268(1-2):25-30. PubMed ID: 19931343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
    Ishii Y; Pirkmaier A; Alvarez JV; Frank DA; Keselman I; Logothetis D; Mandeli J; O'Connell MJ; Waxman S; Germain D
    J Natl Cancer Inst; 2006 Sep; 98(17):1238-47. PubMed ID: 16954476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
    Gorski DH; Beckett MA; Jaskowiak NT; Calvin DP; Mauceri HJ; Salloum RM; Seetharam S; Koons A; Hari DM; Kufe DW; Weichselbaum RR
    Cancer Res; 1999 Jul; 59(14):3374-8. PubMed ID: 10416597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines.
    Wagenblast J; Hambek M; Baghi M; Knecht R
    Anticancer Res; 2008; 28(2A):687-92. PubMed ID: 18507008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.
    Marchi E; Paoluzzi L; Scotto L; Seshan VE; Zain JM; Zinzani PL; O'Connor OA
    Clin Cancer Res; 2010 Jul; 16(14):3648-58. PubMed ID: 20501616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Radiomodifying effect of methandrostenolone on laryngeal cancer cells].
    Bordiushkov IuN; Kucherova TI; Kisliakova ND; Vagner VP; Zubkova TV
    Eksp Onkol; 1987; 9(2):57-9. PubMed ID: 3582242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B.
    Ko BS; Chang TC; Chen CH; Liu CC; Kuo CC; Hsu C; Shen YC; Shen TL; Golubovskaya VM; Chang CC; Shyue SK; Liou JY
    Life Sci; 2010 Jan; 86(5-6):199-206. PubMed ID: 20006625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.